Retrospective cohort study shows that increased lactate dehydrogenase levels elevate cardiac and cerebrovascular risks in hypertensive patients, suggesting stronger biomarkers are needed.
Hui Wang,1â 5,* Nanfang Li,1â 5,* Mulalibieke Heizhati,1â 5 Qing Zhu,1â 5 Ling Yao,1â 5 Huimin Ma,1â 5 Qixin Wang,1â 5 Xiaohong Liu,1â 5 Bahejiamali Nuerbolati,1â 5 Jing Hong1â 5 1Hypertension Center of Peopleâs Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, Peopleâs Republic of China; 2Xinjiang Hypertension Institute, Urumqi, Xinjiang, Peopleâs Republic of China; 3NHC Key Laboratory of Hypertension Clinical Research, Urumqi, Xinjiang, Peopleâs Republic of China; 4Key Laboratory of Xinjiang Uygur Autonomous Region âHypertension Research Laboratoryâ, Urumqi, Xinjiang, Peopleâs Republic of China; 5Xinjiang Clinical Medical Research Center for Hypertension (Cardio-Cerebrovascular) Diseases, Urumqi, Xinjiang, Peopleâs Republic of China*These authors contributed equally to this workCorrespondence: Nanfang Li, Hypertension Center of Peopleâs Hospital of Xinjiang Uygur Autonomous Region, No. 91 Tianchi Road, Urumqi, Xinjiang, Peopleâs Republic of China, Tel +86 8564818, Email lnanfang2016@sina.comBackground: As of 2023, cardiovascular disease (CVD) affects 626 million people globally, imposing a heavy burden on both society and families. Despite advances in antihypertensive therapy, residual risk persists, underscoring the need for potential biomarkers to optimize risk stratification. Lactate dehydrogenase (LDH), traditionally a marker of tissue injury, may reflect metabolic or inflammatory stress associated with vascular damage. This study investigates the association between annual cumulative LDH exposure and incident major adverse cardiac and cerebrovascular events (MACCE) in hypertensive patients, providing insights for prevention strategies.Methods: In this retrospective cohort study, we included hypertensive patients treated at a large tertiary hospital in Urumqi, China, from January 2011 to April 2025. Kaplan-Meier curves visualized survival differences, and Cox proportional hazards models assessed the association between annual LDH_AUC and MACCE risk. Stratified and sensitivity analyses evaluated robustness, while C-statistics compared the predictive performance of annual LDH_AUC versus single-timepoint LDH.Results: During a median follow-up period of 47 months, a total of 879 new MACCE were recorded. The research results showed that whether the annual LDH_AUC was used as a continuous variable or a categorical variable, an increase in annual LDH_AUC would increase the risk of MACCE (HR=1.012, 95% CI, 1.007â 1.017; HR=1.431, 95% CI, 1.185â 1.727). Moreover, the predictive value of annual LDH_AUC for MACCE is superior to that of a single LDH measurement.Conclusion: In hypertensive patients, elevated annual LDH_AUC levels is associated with an elevated risk MACCE.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: